[go: up one dir, main page]

KR880004810A - 소화성 궤양 치료제 - Google Patents

소화성 궤양 치료제 Download PDF

Info

Publication number
KR880004810A
KR880004810A KR870011129A KR870011129A KR880004810A KR 880004810 A KR880004810 A KR 880004810A KR 870011129 A KR870011129 A KR 870011129A KR 870011129 A KR870011129 A KR 870011129A KR 880004810 A KR880004810 A KR 880004810A
Authority
KR
South Korea
Prior art keywords
peptic ulcer
formula
compound
therapeutic agent
oxohexyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR870011129A
Other languages
English (en)
Other versions
KR950007101B1 (ko
Inventor
마사오 사꾸라이
마사요시 고또
토시쬬 타나까
Original Assignee
호르스트 바에쉐
훽스트 제펜 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 호르스트 바에쉐, 훽스트 제펜 리미티드 filed Critical 호르스트 바에쉐
Publication of KR880004810A publication Critical patent/KR880004810A/ko
Application granted granted Critical
Publication of KR950007101B1 publication Critical patent/KR950007101B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

내용 없음

Description

소화성 궤양 치료제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. 유효량의 하기 일반식(Ⅰ)의 화합물 하나 이상 및 약제학적으로 허용되는 담체 또는 부형제로 이루어짐을 특징으로 하는 소화성 궤양 치료제.
    상기식에서 R1은 4-옥소펜틸 또는 5-옥소헥실이고, R2는 메틸 또는 에틸이며, R3는 C2-C4-알킬이다.
  2. 제1항에 있어서, 일반식(Ⅰ)에서의 R1이 5-옥소헥실이고, R2가 메틸이며, R3가 프로필임을 특징으로 하는 치료제
  3. 제1항 또는 제2항에서 정의한 일반식(Ⅰ)의 화합물 하나 이상의 유효량을 생리학적으로 허용되는 담체 또는 부형제와 함께 적합한 투여 형태로 제조함을 특징으로 하여, 소화성 궤양 치료제를 제조하는 방법.
  4. 소화성 궤양을 앓고 있는 사람에게 제1항 또는 제2항에서 정의한 일반식(Ⅰ)의 화합물 하나 이상의 유효량을 약제학적 조성물의 형태로 투여함을 특징으로 하여 소화성 궤양을 앓고 있는 사람을 치료하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870011129A 1986-10-06 1987-10-06 소화성 궤양 치료제 Expired - Fee Related KR950007101B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP236078/86 1986-10-06
JP23607886 1986-10-06
JP236078 1986-10-06

Publications (2)

Publication Number Publication Date
KR880004810A true KR880004810A (ko) 1988-06-27
KR950007101B1 KR950007101B1 (ko) 1995-06-30

Family

ID=16995393

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870011129A Expired - Fee Related KR950007101B1 (ko) 1986-10-06 1987-10-06 소화성 궤양 치료제

Country Status (16)

Country Link
US (1) US4845102A (ko)
EP (1) EP0266559B1 (ko)
JP (1) JPS63225317A (ko)
KR (1) KR950007101B1 (ko)
AT (1) ATE75399T1 (ko)
AU (1) AU595379B2 (ko)
CA (1) CA1297021C (ko)
DE (1) DE3778642D1 (ko)
DK (1) DK169305B1 (ko)
ES (1) ES2032797T3 (ko)
GR (1) GR3004848T3 (ko)
HU (1) HU200098B (ko)
IE (1) IE60863B1 (ko)
IL (1) IL84096A (ko)
PT (1) PT85866B (ko)
ZA (1) ZA877454B (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2661666B2 (ja) * 1988-02-19 1997-10-08 ヘキスト薬品工業株式会社 抗消化性潰瘍剤
DD298051A5 (de) * 1989-08-16 1992-02-06 ��@���������@�������k�� Verfahren zur herstellung eines therapeutischen agens zur behandlung von verdauungskrankheiten
DE4025371A1 (de) * 1990-08-10 1992-02-13 Kali & Salz Ag Verfahren zur reinigung von elektrostatisch gewonnenem steinsalz
EP0570831A2 (de) * 1992-05-20 1993-11-24 Hoechst Aktiengesellschaft Verwendung von Xanthinderivaten zur Behandlung von Nervenschädigungen nach Unterbrechung der Blutzirkulation
US5780476A (en) * 1992-11-16 1998-07-14 Cell Therapeutics, Inc. Hydroxyl-containing xanthine compounds
US6693105B1 (en) 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US20030207901A1 (en) * 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2330742C2 (de) * 1973-06-16 1982-07-29 Hoechst Ag, 6000 Frankfurt 1-(Oxoalkyl)-3-methyl-7-alkylxanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
CH608236A5 (ko) * 1974-01-22 1978-12-29 Wuelfing J A Fa
CA1075690A (en) * 1974-12-13 1980-04-15 Hoechst Aktiengesellschaft Xanthine derivatives
US4511557A (en) * 1981-08-24 1985-04-16 Gauri Kailash Kumar Pharmaceutical composition
IT1200944B (it) * 1982-08-10 1989-01-27 Malesci Sas Derivati xantinici,procedimento per la loro preparazione,composizione farmaceutiche che il contengono e loro impiego terapeutico
US4636507A (en) * 1984-04-30 1987-01-13 Hoechst-Roussel Pharmaceuticals Inc. Host defense mechanism enhancement

Also Published As

Publication number Publication date
IE872656L (en) 1988-04-06
GR3004848T3 (ko) 1993-04-28
US4845102A (en) 1989-07-04
IL84096A0 (en) 1988-03-31
KR950007101B1 (ko) 1995-06-30
AU595379B2 (en) 1990-03-29
DK520787D0 (da) 1987-10-05
DK520787A (da) 1988-04-07
ES2032797T3 (es) 1993-03-01
HU200098B (en) 1990-04-28
JPS63225317A (ja) 1988-09-20
ATE75399T1 (de) 1992-05-15
EP0266559A2 (en) 1988-05-11
EP0266559B1 (en) 1992-04-29
AU7935887A (en) 1988-04-14
EP0266559A3 (en) 1990-06-06
DE3778642D1 (de) 1992-06-04
PT85866A (en) 1987-11-01
ZA877454B (en) 1988-05-25
DK169305B1 (da) 1994-10-10
IL84096A (en) 1991-07-18
HUT46214A (en) 1988-10-28
CA1297021C (en) 1992-03-10
IE60863B1 (en) 1994-08-24
PT85866B (pt) 1990-07-31

Similar Documents

Publication Publication Date Title
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
KR900701282A (ko) 심장 또는 뇌의 허혈성 질환의 치료, 예방제
KR920002144A (ko) 아연 l-카르노신 염 또는 이의 착화합물을 유효성분으로 함유하는 염증성 장질환 예방 및 치료제
KR950007848A (ko) (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법
KR890011596A (ko) 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도
KR900016135A (ko) 피부 및 점막-상피의 질환 치료용 4-퀴놀린 카복실산 유도체
KR880004810A (ko) 소화성 궤양 치료제
ATE55248T1 (de) Arzneimittelkombination.
KR890003752A (ko) 2-피리미디닐-피페라딘 유도체의 용도
KR890006227A (ko) 페놀-함유 진해성 액체 조성물
KR890012942A (ko) 5-치환된 오르니틴 유도체
KR890008136A (ko) 항균성 9-데옥소-9a-알릴 및 프로파길-9a-아자-9a-호모에리트로 마이신 A 유도체
KR910002442A (ko) 안구질환을 치료하는 방법 및 제약학적 조성물
KR910005886A (ko) 안정화 백혈구 인터페론
KR940013503A (ko) 동맥경화증의 예방 또는 치료용 약제학적 조성물
KR880001596A (ko) 디하이드로피리딘 화합물-함유 뇌기능이상 치료제
ATE1442T1 (de) Pharmazeutisches mittel, enthaltend all-e- oder 13-z-7,8-dehydro-retinsaeure und verfahren zu seiner herstellung.
KR870011135A (ko) 시스-6-(4-아세트아닐리도)-8,9-디메톡시-2-메틸-1,2,3,4,4a,10b- 헥사이드로-벤조〔c〕〔1,6〕 나프티리딘으로 구성된 약학적 조성물 및 그것의 용도
KR830009776A (ko) 세포 보호 유도방법
KR900701273A (ko) 진토성 에르골린 유도체
KR880009656A (ko) 국소 치근막 질환의 치료 또는 예방법
KR900017599A (ko) 종양 치료용 약학 조성물
KR870010871A (ko) 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법
KR880001630A (ko) 5-플루오로우라실 유도체 및 그의 용도
KR910002456A (ko) 당뇨병 치료용 제약 조성물

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 19980701

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 19980701

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000